Immunological mechanisms of sublingual immunotherapy

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 6, 2014, Pages 564-569

  Allam, Jean Pierre ^a   Novak, Natalija ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Dendritic cells; Regulatory T cells; Sublingual immunotherapy; Th1; Th2

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN G;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; BRONCHUS MUCOSA; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; MOUTH MUCOSA; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SUBLINGUAL IMMUNOTHERAPY; TH1 CELL; TH2 CELL; ANIMAL; HYPERSENSITIVITY; IMMUNOLOGY; MOUSE; PROCEDURES; T LYMPHOCYTE;

ALLERGENS; ANIMALS; HUMANS; HYPERSENSITIVITY; MICE; SUBLINGUAL IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 84927695006     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000118     Document Type: Review

References (52)

1. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; CD001936.
2. Calderon M, Cardona V, Demoly P. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions. Allergy 2012; 67:462-476.
3. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003; 111:437-448.
4. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2010; 66:740-752.
5. Durham SR. Mechanisms of mucosal inflammation in the nose and lungs. Clin Exp Allergy 1998; 28 (Suppl 2):11-16.
6. van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013; 131:1204-1212.
7. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol 2014; 133:621-631.
8. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-426.
9. Romani N, Clausen BE, Stoitzner P. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev 2010; 234:120-141.
10. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signalsinduce tolerance or immunity? Trends Immunol 2002; 23:445-449.
11. Mascarell L, Lombardi V, Louise A, et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. J Allergy Clin Immunol 2008; 122:603-609.
12. Nagai Y, Shiraishi D, Tanaka Y, et al. Transportation of sublingual antigens across sublingual ductal epithelial cells to the ductal antigen-presenting cells in mice. Clin Exp Allergy 2014. [Epub ahead of print]
13. Lombardi V, Van Overtvelt L, Horiot S, et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy 2008; 38:1819-1829.
14. Mascarell L, Saint-Lu N, Moussu H, et al. Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice. Mucosal Immunol 2011; 4:638-647.
15. Allam JP, Niederhagen B, Bucheler M, et al. Comparative analysis of nasal and oral mucosa dendritic cells. Allergy 2006; 61:166-172.
16. Allam JP, Novak N, Fuchs C, et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003; 112:141-148.
17. Allam JP, Peng WM, Appel T, et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008; 121:368-374.
18. Allam JP, Bieber T, Novak N. Dendritic cells as potential targets for mucosal immunotherapy. Curr Opin Allergy Clin Immunol 2009; 9:554-557.
19. Allam JP, Klein E, Bieber T, Novak N. Transforming growth factor-beta1 regulates the expression of the high-affinity receptor for IgE on CD34 stem cell-derived CD1a dendritic cells in vitro. J Invest Dermatol 2004; 123:676-682.
20. Pfaar O, Barth C, Jaschke C, et al. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2011; 154:336-344.
21. Allam JP, Wurtzen PA, Reinartz M, et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta 1 and IL-10-producing properties. J Allergy Clin Immunol 2010; 126:U638-U645.
22. Allam JP, Stojanovski G, Friedrichs N, et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 2008; 63:720-727.
23. Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606.
24. Demoly P, Calderon MA. Dosing and efficacy in specific immunotherapy. Allergy 2011; 66 (Suppl 95):38-40.
25. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-809.
26. Kildsgaard J, Brimnes J, Jacobi H, Lund K. Sublingual immunotherapy in sensitized mice. Ann Allergy Asthma Immunol 2007; 98:366-372.
27. Rask C, Brimnes J, Lund K. Shorter dosing intervals of sublingual immunotherapy lead to more efficacious treatment in a mouse model of allergic inflammation. Scand J Immunol 2010; 71:403-412.
28. Lima MT, Wilson D, Pitkin L, et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32:507-514.
29. Marcucci F, Incorvaia C, Sensi L, et al. Lack of inflammatory cells in the oral mucosa of subjects undergoing sublingual immunotherapy. Int J Immuno-pathol Pharmacol 2008; 21:609-614.
30. Allam JP, Wuestenberg E, Wolf H, et al. Immunologic response and safety in birch pollen sublingual versus oral vestibule immunotherapy: a pilot study. J Allergy Clin Immunol 2014; 133:1757-1759.
31. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008; 121:1467-1472.
32. Wilson DR, Irani AM, Walker SM, et al. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001; 31:1705-1713.
33. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-1365.
34. Passalacqua G, Albano M, Riccio A, et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104:964-968.
35. Marogna M, Spadolini I, Massolo A, et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J Allergy Clin Immunol 2005; 115:1184-1188.
36. Bahceciler NN, Arikan C, Taylor A, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136:287-294.
37. Kaminuma O, Suzuki K, Mori A. Effect of sublingual immunotherapy on antigen-induced bronchial and nasal inflammation in mice. Int Arch Allergy Immunol 2010; 152 (Suppl 1):75-78.
38. Brimnes J, Kildsgaard J, Jacobi H, Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy 2007; 37:488-497.
39. Yu HQ, Li XH, Guo H, et al. Sublingual immunotherapy efficacy of Derma-tophagoides farinae vaccine in a murine asthma model. Int Arch Allergy Immunol; 152:; 2010:41-48.
40. Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-713.
41. O'Hehir RE, Gardner LM, de Leon MP, et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009; 180:936-947.
42. Nieminen K, Valovirta E, Savolainen J. Clinical outcome and IL-17, IL-23 IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy. Pediatr Allergy Immunol 2000; 21:e174-e184.
43. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006; 61:1184-1190.
44. Cosmi L, Santarlasci V, Angeli R, et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy 2006; 36:261-272.
45. Suarez-Fueyo A, Ramos T, Galan A, et al. Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation. J Allergy Clin Immunol 2014; 133:130-138.
46. Dehlink E, Eiwegger T, Gerstmayr M, et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006; 36:32-39.
47. Rolinck-Werninghaus C, Kopp M, Liebke C, et al. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005; 136:134-141.
48. Dahl R, Kapp A, Colombo G, et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121:512-518.
49. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:131-138.
50. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-1345.
51. Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010; 40:598-606.
52. Aasbjerg K, Backer V, Lund G, et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy 2014; 44:417-428.